Use case
Secreted VHH and nanobody expression in Pichia with ranked CDS panels, secretion-leader design, and structure-confidence checks.
The problem
VHH domains and nanobodies are small, stable, and suitable for Pichia secretion. But achieving soluble secreted output depends on codon optimization, signal-peptide selection, and avoiding aggregation-prone sequence features. Teams often default to α-MF without evaluating alternatives, and lack a systematic way to rank construct variants before synthesis.
How Kairos helps
Kairos evaluates your VHH sequence against Pichia usage tables, ranks multiple CDS candidates with per-axis rationales (codon fidelity, synthesis safety, 5′ initiation, developability), and compares secretion-leader options with cited evidence. The structure-confidence check flags aggregation-prone or poorly folded candidates before you spend on synthesis.
Honesty boundary: Kairos ranks dry-lab design quality. It does not predict expression level or titer. The output is a design recommendation grounded in directional evidence.
Leader comparison
α-MF, SUC2, and native signal peptides compared with cited evidence — no defaulting to α-MF.
Folding and aggregation flags
Boltz-2 confidence screens flag poorly folded or aggregation-prone candidates early.
Ranked CDS panel
Candidates ranked with per-axis rationales: codon fidelity, synthesis safety, 5′ initiation, developability.
Worked example
Minutes, not weeks. Every construct scored, every claim cited, every limit stated.